Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2020-05-05 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides avser att genomföra en riktad nyemission
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated May 5, 2020, titled "Oncopeptides avser att genomföra en riktad nyemission" (Oncopeptides intends to conduct a directed new share issue). The text explicitly discusses the intention to raise capital (bruttolikvid om cirka 1 180 miljoner SEK) through a directed share issue, detailing the bookbuilding process, use of proceeds (financing commercial launch, clinical development), and lock-up agreements. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing plan itself.
2020-05-05 Swedish
Oncopeptides intends to carry out a directed share issue
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "Oncopeptides intends to carry out a directed share issue" and details the mechanics of raising capital through a share issuance, including the subscription price, bookbuilding process, intended use of proceeds (funding commercial launch, clinical development), and lock-up agreements. This content directly relates to fundraising, capital structure changes, and the issuance of new securities. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report (RPA/RNS), but the core subject matter is capital raising.
2020-05-05 English
Annual Report 2019
Annual Report Classification · 1% confidence The document is titled 'ÅRSREDOVISNING 2019' (Annual Report 2019) for the company Oncopeptides. It contains a comprehensive overview of the company's activities, financial statements (including consolidated and parent company reports), management reports, audit reports, and governance information for the fiscal year 2019. It is a full-length annual report, not an announcement or a summary. FY 2019
2020-04-28 Swedish
Annual Report 2019
Annual Report Classification · 1% confidence The document is clearly identified as an 'ANNUAL REPORT 2019' for the company Oncopeptides. It contains a comprehensive overview of the company's activities, financial statements (consolidated and parent company), audit reports, and management discussions for the full fiscal year. It is not an announcement of a report, but the report itself, and it exceeds the length criteria for a summary document. FY 2019
2020-04-28 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 1% confidence The document explicitly details a change in shareholding quantity and percentage for a specific holder (Swedbank Robur Fonder AB) in an issuer (Oncopeptides AB). It tracks the 'Before the transaction' and 'After the transaction' share counts and voting rights, noting the 'Reason for major shareholding notification Buy'. This structure perfectly matches the definition of a Major Shareholding Notification, which tracks when an investor crosses ownership thresholds. The corresponding code is MRQ.
2020-04-14 English
Oncopeptides tillkännager att den finala tumörsvarsfrekvensen i den pivotala melflufenstudien HORIZON var 26% för trippelklassrefraktära RRMM- patienter
Earnings Release Classification · 1% confidence The document is explicitly titled "Pressmeddelande" (Press Release) dated March 26, 2020. It announces the final tumor response rate from the pivotal HORIZON study for melflufen and states that these results will form the basis for an upcoming NDA application to the FDA. This structure—a formal announcement of key clinical trial results intended for immediate public disclosure, often preceding a formal report filing—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release detailing key financial/clinical milestones and results, and not a full quarterly report (IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as it serves as the initial public disclosure of performance metrics. It is not an RPA because it contains the substantive results, not just an announcement that a report is available. It is not an AR because it is a press release, not the formal audit report itself. It is not an IR because it is a press release summarizing results, not the comprehensive interim report. Q2 2020
2020-03-26 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.